Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 9.12 USD -1.62% Market Closed
Market Cap: 2.8B USD
Have any thoughts about
Iovance Biotherapeutics Inc?
Write Note

Iovance Biotherapeutics Inc
Preferred Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Iovance Biotherapeutics Inc
Preferred Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Preferred Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Preferred Shares Outstanding
$2.8m
CAGR 3-Years
1%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Preferred Shares Outstanding
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Preferred Shares Outstanding
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Preferred Shares Outstanding
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Preferred Shares Outstanding
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Preferred Shares Outstanding
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Iovance Biotherapeutics Inc
Glance View

Market Cap
2.8B USD
Industry
Biotechnology

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 319 full-time employees. The company went IPO on 2008-06-20. The firm is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The company has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). The company is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

IOVA Intrinsic Value
13.1 USD
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Iovance Biotherapeutics Inc's Preferred Shares Outstanding?
Preferred Shares Outstanding
2.8m USD

Based on the financial report for Sep 30, 2024, Iovance Biotherapeutics Inc's Preferred Shares Outstanding amounts to 2.8m USD.

What is Iovance Biotherapeutics Inc's Preferred Shares Outstanding growth rate?
Preferred Shares Outstanding CAGR 5Y
-5%

Over the last year, the Preferred Shares Outstanding growth was 2%. The average annual Preferred Shares Outstanding growth rates for Iovance Biotherapeutics Inc have been 1% over the past three years , -5% over the past five years .

Back to Top